Graftys, a French biotech startup has a range of raw materials which can replace human bones and today it has announced the completion of a €4.1M funding round. The funding round was co-led by GO Capital (Rennes, France), Innovation Fund (Brussels, Belgium), Meusinvest (Liège, Belgium) and TheClubDeal (Brussels, Belgium).
The development of its operations took place in Belgium and the reinforcement of its French operations with the creation of a design and industrialisation unit in Nantes. Founded in 2005 on the research works of Pr. Jean-Michel Bouler, Graftys develops, manufactures and markets patented synthetic orthopedic biomaterials, in particular, new generations of resorbable calcium-phosphate cements, for reconstructive orthopedic surgery.